Bo Xuanyu
University of Glasgow, Gilmorehill, Glasgow, Scotland G128QQ UK.
EPMA J. 2025 Mar 26;16(2):351-386. doi: 10.1007/s13167-025-00405-8. eCollection 2025 Jun.
Microalgae are emerging as innovative bioresources with diverse therapeutic applications, particularly in cardiovascular health, neuroprotection, anti-inflammatory, and antioxidant responses. These bioactive compounds effectively reduce inflammatory mediators, mitigate oxidative stress, and support mitochondrial health-critical factors in exercise performance, recovery, and chronic disease management. Notably, microalgae such as and exhibit promising biological activities in preclinical and limited clinical studies, including anti-inflammatory and neuroprotective effects. However, large-scale, randomized controlled trials (RCTs) remain scarce, limiting their clinical translation. Although preliminary evidence suggests potential benefits for sports performance, oxidative stress reduction, and cognitive function, most studies are small-scale, preclinical, or observational. Large, well-powered RCTs are needed to confirm their efficacy and safety. Within the framework of Predictive, Preventive, and Personalized Medicine (PPPM/3PM), this review explores microalgae's potential in predictive diagnostics, targeted prevention, and individualized supplementation strategies. Despite promising findings, clinical application requires a cautious approach due to insufficient high-quality trials supporting microalgae-based interventions in medical practice. Future research should prioritize RCTs, pharmacokinetic studies, and long-term safety assessments to establish evidence-based guidelines for their use in health and disease management.
微藻正成为具有多种治疗应用的创新生物资源,特别是在心血管健康、神经保护、抗炎和抗氧化反应方面。这些生物活性化合物能有效减少炎症介质、减轻氧化应激,并支持线粒体健康,而线粒体健康是运动表现、恢复和慢性病管理中的关键因素。值得注意的是,诸如[具体微藻名称1]和[具体微藻名称2]等微藻在临床前和有限的临床研究中展现出了有前景的生物活性,包括抗炎和神经保护作用。然而,大规模随机对照试验(RCT)仍然稀缺,限制了它们的临床转化。尽管初步证据表明其对运动表现、减少氧化应激和认知功能有潜在益处,但大多数研究规模较小、属于临床前研究或观察性研究。需要大规模、有力的RCT来证实其疗效和安全性。在预测、预防和个性化医学(PPPM/3PM)框架内,本综述探讨了微藻在预测诊断、靶向预防和个性化补充策略方面的潜力。尽管有令人鼓舞的发现,但由于缺乏高质量试验支持微藻在医学实践中的干预措施,临床应用仍需谨慎。未来研究应优先进行RCT、药代动力学研究和长期安全性评估,以建立基于证据的指南,指导其在健康和疾病管理中的应用。